Cervical Boost by Ablative Stereotactic Radiotherapy (SABR) vs Brachytherapy in Patients With Cervical Carcinoma

Background Cervical cancer (CaCu) is the fourth cause of death in women. In patients with locally advanced disease, the treatment of choice is CT/RT, followed by additional boosting with brachytherapy (BT). There is an international decrease in the use of this technique due to financial restrictions. Given the difficulties in using brachytherapy as a boost, several series have described promising results in local control using boost with highly conformal techniques such as stereotactic body radiotherapy (SBRT). On the other hand, prospective studies are scarce and with controversial results. N

Trial Details

NCT ID
NCT06560697
Phase
NA
Sponsor
National Institute of Cancerología
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • SABR VS Intracavitary 3D Brachytherapy
Locations (sample)
  • Mexico City, Tlalpan, Mexico|19.42847,-99.12766

Key Eligibility Criteria

  • People with cervical cancer \>18 years of age.
  • Signed informed consent form approved by the regulatory committees of both institutes and, obtained before each procedure related to the protocol, …
  • Able to comply with scheduled visits, treatment schedules, laboratory and imaging studies, and completing quality of life questionnaires.
  • Histological confirmation of CaCu and staged as IB3-IIIC1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →